The E. coli L-asparaginase V27T mutant: structural and functional characterization and comparison with theoretical predictions
- PMID: 36310372
- PMCID: PMC10673687
- DOI: 10.1002/1873-3468.14526
The E. coli L-asparaginase V27T mutant: structural and functional characterization and comparison with theoretical predictions
Abstract
Bacterial L-asparaginases have been used for over 40 years as anticancer drugs. Ardalan et al. (Medical Hypotheses 112, 7-17, 2018) proposed that the V27T mutant of Escherichia coli type II L-asparaginase, EcAII(V27T), should display altered biophysical and catalytic properties compared to the wild-type enzyme, EcAII(wt), rendering it more favourable as a pharmaceutical. They postulated that EcAII(V27T) would exhibit reduced glutaminolytic activity and be more stable compared to EcAII(wt). Their postulates, however, were purely theoretical. Here, we characterized experimentally selected properties of EcAII(V27T). We found asparaginolytic activity of this mutant unchanged, whereas its glutaminolytic activity was fourfold lower compared with EcAII(wt). We did not observe significant differences in stabilities of EcAII(wt) and EcAII(V27T). Crystal structures of the complexes with L-Asp and L-Glu showed considerable differences in binding modes of both substrates.
Keywords: X-ray crystallography; asparaginolytic activity; bacterial L-asparaginases; biological assembly; glutaminolytic activity; single-site mutation.
Published 2022. This article is a U.S. Government work and is in the public domain in the USA.
Figures



Similar articles
-
Crystal structure of active site mutant of antileukemic L-asparaginase reveals conserved zinc-binding site.FEBS J. 2014 Sep;281(18):4097-111. doi: 10.1111/febs.12906. Epub 2014 Jul 28. FEBS J. 2014. PMID: 25040257
-
Novel mutant of Escherichia coli asparaginase II to reduction of the glutaminase activity in treatment of acute lymphocytic leukemia by molecular dynamics simulations and QM-MM studies.Med Hypotheses. 2018 Mar;112:7-17. doi: 10.1016/j.mehy.2018.01.004. Epub 2018 Jan 30. Med Hypotheses. 2018. PMID: 29447943
-
Functional and structural evaluation of the antileukaemic enzyme L-asparaginase II expressed at low temperature by different Escherichia coli strains.Biotechnol Lett. 2020 Nov;42(11):2333-2344. doi: 10.1007/s10529-020-02955-5. Epub 2020 Jul 7. Biotechnol Lett. 2020. PMID: 32638188
-
Structural and biochemical properties of L-asparaginase.FEBS J. 2021 Jul;288(14):4183-4209. doi: 10.1111/febs.16042. Epub 2021 Jun 19. FEBS J. 2021. PMID: 34060231 Review.
-
[Bacterial recombinant L-asparaginases: properties, structure and anti-proliferative activity].Biomed Khim. 2015 May-Jun;61(3):312-24. doi: 10.18097/PBMC20156103312. Biomed Khim. 2015. PMID: 26215408 Review. Russian.
Cited by
-
Biochemical and Biophysical Divergences between Two Escherichia coli l-Asparaginase II Variants: Potential for Using EcA2-K12 as a Biosimilar.Biochemistry. 2025 Jul 15;64(14):3015-3029. doi: 10.1021/acs.biochem.4c00663. Epub 2025 Apr 16. Biochemistry. 2025. PMID: 40237204 Free PMC article.
-
Towards a dependable data set of structures for L-asparaginase research.Acta Crystallogr D Struct Biol. 2024 Jul 1;80(Pt 7):506-527. doi: 10.1107/S2059798324005461. Epub 2024 Jun 27. Acta Crystallogr D Struct Biol. 2024. PMID: 38935343 Free PMC article.
References
-
- Lubkowski J, Wlodawer A. Structural and biochemical properties of L-asparaginase. FEBS J. 2021;288:4183–209. - PubMed
-
- Mashburn LT, Wriston JC. Tumor inhibitory effect of L-asparaginase from Escherichia coli. Arch Biochem Biophys. 1964;105:450–2. - PubMed
-
- Roberts J, Prager MD, Bachynsky N. The antitumor activity of Escherichia coli L-asparaginase. Cancer Res. 1966;26:2213–7. - PubMed
-
- Dolowy WC, Henson D, Cornet J, Sellin H. Toxic and antineoplastic effects of l-asparaginase: study of mice with lymphoma and normal monkeys and report on a child with leukemia. Cancer. 1966;19:1813–9. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Molecular Biology Databases